Cart
sales@molnova.com
NQO1 substrate
CAS No. 2304503-05-5
NQO1 substrate( —— )
Catalog No. M33225 CAS No. 2304503-05-5
NQO1 substrate is a highly potent NQO1 substrate with potential antitumor activity for leukemia research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 2MG | 49 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNQO1 substrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionNQO1 substrate is a highly potent NQO1 substrate with potential antitumor activity for leukemia research.
-
DescriptionNQO1 substrate acts as an efficient NQO1 substrate and may be a new option for the treatment of NQO1-overexpresssing drug-resistant NSCLC.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetNADPH
-
RecptorNADPH
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2304503-05-5
-
Formula Weight268.18
-
Molecular FormulaC13H2F2N4O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (466.10 mM; Ultrasonic )
-
SMILESFc1cc2C(=O)c3nc(C#N)c(nc3-c2cc1F)C#N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wu X, et al. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer. J Med Chem. 2018 Dec 27;61(24):11280-11297.?
molnova catalog
related products
-
Acetohexamide
Acetohexamide is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2.
-
S29434
S29434 (NMDPEF) is a potent competitiveinhibitor of quinone reductase 2 (QR2;IC50:5-16nM).
-
GSK2795039
GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis.
